Spondylitis News and Research

RSS
Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Potential predictors of spinal damage progression in people with spondyloarthritis

Potential predictors of spinal damage progression in people with spondyloarthritis

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Janssen Biotech receives FDA approval for Remicade to treat UC in children

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Big news for ankylosing spondylitis sufferers

Big news for ankylosing spondylitis sufferers

New genetic research on Ankylosing Spondylitis

New genetic research on Ankylosing Spondylitis

New genetic clues about ankylosing spondylitis

New genetic clues about ankylosing spondylitis

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Researchers create protein molecule for new anti-inflammatory therapies

Researchers create protein molecule for new anti-inflammatory therapies

The Arthritis Society awards $3.5 million grant for new research and training

The Arthritis Society awards $3.5 million grant for new research and training

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion